

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI675286

| | |
|---|-----------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| Oxiant Discovery AB | 09/26/2024 |
| RECEIVING PARTY DATA | |
| Company Name: | Sentonix, Inc. |
| Street Address: | 1167 Massachusetts Ave, |
| City: | Arlington |
| State/Country: | MASSACHUSETTS |
| Postal Code: | 02476 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Patent Number: | 11434237 |
| CORRESPONDENCE DATA | |
| Fax Number: | 9374496405 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | (937)449-6400 |
| Email: | daytonipdocket@dinsmore.com |
| Correspondent Name: | Jessica Desmarais |
| Address Line 1: | One S. Main Street |
| Address Line 2: | Suite 1300 |
| Address Line 4: | Dayton, OHIO 45402 |
| ATTORNEY DOCKET NUMBER: | P026686US |
| NAME OF SUBMITTER: | Jessica Desmarais |
| SIGNATURE: | Jessica Desmarais |
| DATE SIGNED: | 12/05/2024 |
| Total Attachments: 7 | |
| source=Oxiant to Sentonix Patent Assignment Agreement#page1.tiff | |
| source=Oxiant to Sentonix Patent Assignment Agreement#page2.tiff | |
| source=Oxiant to Sentonix Patent Assignment Agreement#page3.tiff | |
| source=Oxiant to Sentonix Patent Assignment Agreement#page4.tiff | |
| source=Oxiant to Sentonix Patent Assignment Agreement#page5.tiff | |

source=Oxiant to Sentonix Patent Assignment Agreement#page6.tiff

source=Oxiant to Sentonix Patent Assignment Agreement#page7.tiff

ASSIGNMENT OF U.S. AND NON-U.S. PATENT RIGHTS

THIS ASSIGNMENT OF U.S. AND NON-U.S. PATENT RIGHTS (this “Assignment”), made as of, September 26, 2024, is entered into by and between Sentonix, Inc. (“Assignee”) and Oxiant Discovery AB (“Assignor”).

WHEREAS, Assignor and Assignee are party to that certain Asset Purchase Agreement, dated September 26, 2024 (the “Purchase Agreement”), pursuant to which Assignor agreed to sell, assign, transfer, convey and deliver certain assets to Assignee, and Assignee agreed to accept from Assignor, all of Assignor’s right, title, and interest, including all of Assignor’s right, title, and interest in and to the patents and patent applications identified on Schedule A of this Assignment, and all inventions, registrations, renewals, provisionals, non-provisionals, reissues, continuations, continuations in-part, divisionals, revisions, renewals, reexaminations and extensions captured in those patents and patent applications (the “Assigned Patents”);

NOW THEREFORE, in consideration of the promises and the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by both Assignor and Assignee, Assignor and Assignee hereby agree as follows:

1. Definitions. Capitalized terms used but not defined herein shall have the meanings accorded to them in the Purchase Agreement.
2. Assignment. Assignor hereby sells, conveys, assigns, delivers, and transfers to Assignee all of Assignor’s right, title and interest in and to the Assigned Patents, including (i) any and all rights of indirectly or directly claimed rights of priority thereto and renewals thereof; (ii) all patents and patent applications to which any of the Assigned Patents claim priority and all patents and patent applications claiming priority to any of the foregoing; (iii) prosecution history associated with any of the Assigned Patents; (iv) the right to sue and recover for past, present, and future infringements of the foregoing whether accruing before or after the Effective Date (including all rights to claim for injunctive relief, damages, profits, restitution and other legal and equitable relief), and to receive all damages, profits, restitution, payments, costs, fees and other legal and equitable relief associated with the enforcement of such rights, as well as all rights to license, assign, pledge, and/or otherwise exploit such Assigned Patents, and (iv) except as described in the Purchase Agreement, the right to recover and receive any and all royalties, fees, income, payments, and other proceeds in each case now or hereafter due or payable with respect to the Assigned Patents, and Assignee hereby accepts the foregoing sale, conveyance, assignment, delivery, and transfer from Assignor.
3. Authority. The officer that executes this Assignment on behalf of Assignor is authorized to bind and obligate each of the entities defined herein as part of Assignor and covenants that Assignor has not executed and will not execute an agreement in conflict with this Assignment. The officer that executes this Assignment on behalf of Assignee is authorized to bind and obligate the entity defined herein as Assignee.
4. Recordation. Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks, and/or any other applicable governmental entity or registrar, to record Assignee as



the owner of the Assigned Patents, and to issue any and all Assigned Patents to Assignee, as assignee of Assignor's entire right, title and interest in, to, and under the same. Assignee shall have the right to record this Assignment with all applicable governmental authorities and registrars, so as to perfect its ownership of the Assigned Patents.

5. Further Assurances. Assignor shall provide Assignee, its successors, assigns or other legal representatives, reasonable cooperation and assistance at Assignee's request and expense that Assignee deems necessary to effectuate, perfect, and record this Assignment.

6. Purchase Agreement. Nothing in this Assignment, express or implied, is intended to or shall be construed to supersede, modify, replace, amend, rescind, waive, expand, or limit in any way the rights of the parties under, or the terms of, the Purchase Agreement. To the extent that any provision of this Assignment conflicts or is inconsistent with the terms of the Purchase Agreement, the Purchase Agreement shall govern.

7. Amendment. This Assignment may not be modified, amended, altered or supplemented except upon the execution and delivery of a written agreement executed by both Parties.

8. Governing Law. This Assignment shall be governed by, and construed in accordance with, the laws of the U.S. in respect of patent issues and in all other respects by the laws of the State of Delaware, without regard to its conflicts of laws.


9. Counterparts. This Assignment may be executed in one or more counterparts (including by facsimile or electronic .pdf submission), each of which shall be deemed to be an original and all of which shall be deemed to constitute the same agreement.

[Signature page follows]




IN WITNESS WHEREOF, Assignor and Assignee have executed this Assignment as of the date first written above.

ASSIGNOR: **OXIANT DISCOVERY AB**

By: 


Name: Johan Sandell, Director

Title: Chief Executive Officer

By: 


Name: Peter Ström

Title: Director

By: 

Name: Daniel Sohn

Title: Director

By: 

Name: Samuel Svensson

Title: Director

ASSIGNEE: **SENTONIX, Inc.**

By: 

Name: John Beaver

Title: Chief Executive Officer



Schedule A to Patent Assignment

ASSIGNMENT OF U.S. AND NON-U.S. PATENT RIGHTS

Assigned Patents and Applications

| Jurisdiction | Title | Appl. No. | Filing Date |
|--------------------------|---|--------------------------------|--------------------|
| European Patent Office | Selective ligands for tau aggregates | 18755737.6 | 3 August 2018 |
| United Kingdom | Selective ligands for tau aggregates | 1712567.5 (priority filing) | 4 August 2017 |
| United States of America | Selective ligands for tau aggregates | 16/636219 | 3 August 2018 |
| International (PCT) | Selective ligands for tau aggregates | PCT/EP2018/071148 | 3 August 2018 |
| | | | |
| European Patent Office | Selective ligands for tau aggregates | 19718116.7 | 10 April 2019 |
| United Kingdom | Selective ligands for tau aggregates | 1806004.6 (priority filing) | 11 April 2018 |
| United States of America | Selective ligands for tau aggregates | 17/046683 | 10 April 2019 |
| International (PCT) | Selective ligands for tau aggregates | PCT/EP2019/059165 | 10 April 2019 |
| | | | |
| Canada | Selective ligands for tau aggregates | 3154912 | 15 October 2020 |
| European Patent Office | Selective ligands for tau aggregates | 20796516.1 | 15 October 2020 |
| United Kingdom | Selective ligands for tau aggregates | 1914989.7 (priority filing) | 16 October 2019 |
| United States of America | Selective ligands for tau aggregates | 17/768660 | 15 October 2020 |
| International (PCT) | Selective ligands for tau aggregates | PCT/EP2020/079139 | 15 October 2020 |
| | | | |
| United Kingdom | Selective ligands for tau aggregates | 2216351.3 (priority filing) | 3 November 2022 |
| United Kingdom | Selective ligands for tau aggregates | 2312590.9 (priority filing) | 17 August 2023 |



| Jurisdiction | Title | Appl. No. | Filing Date |
|------------------------|---|-------------------|-----------------|
| International (PCT) | Selective ligands for tau aggregates | PCT/EP2023/080605 | 2 November 2023 |



Verification

Transaction 09222115557527981244

Document

5.2 Project Onyx_Patent Assignment Agreement(21321048.1)

Main document

5 pages

Initiated on 2024-09-26 16:06:35 CEST (+0200) by Mikaela Gisslen (MG)

Finalised on 2024-09-26 16:08:15 CEST (+0200)

Initiator

Mikaela Gisslen (MG)

Advokatbyrån Gulliksson AB

mikaela.gisslen@gulliksson.se

+46764951399

Signatories

John Beaver (JB)

jbeaver@sentonixpharma.com



Signed 2024-09-26 16:07:22 CEST (+0200)

Johan Sandell (JS)

Johan.Sandell@oxiantdiscovery.com



Signed 2024-09-26 16:07:26 CEST (+0200)

Peter Ström (PS)

peter.strom@oxiantdiscovery.com



Signed 2024-09-26 16:07:28 CEST (+0200)

Daniel Sohn (DS)

daniel.sohn54@gmail.com



Signed 2024-09-26 16:07:55 CEST (+0200)

Samuel Svensson (SS)

samuel.svensson@oxiantdiscovery.com



Signed 2024-09-26 16:08:15 CEST (+0200)



Verification

Transaction 09222115557527981244

This verification was issued by Scrive. Information in italics has been safely verified by Scrive. For more information/evidence about this document see the concealed attachments. Use a PDF-reader such as Adobe Reader that can show concealed attachments to view the attachments. Please observe that if the document is printed, the integrity of such printed copy cannot be verified as per the below and that a basic print-out lacks the contents of the concealed attachments. The digital signature (electronic seal) ensures that the integrity of this document, including the concealed attachments, can be proven mathematically and independently of Scrive. For your convenience Scrive also provides a service that enables you to automatically verify the document's integrity at: <https://scrive.com/verify>

